Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib +/- Rituximab vs Ibrutinib in R/R MCL
NCT02735876Phase 3Withdrawn
- Sponsor
- Acerta Pharma
- Start
- May 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by Acerta Pharma. Planned start May 2016; status: withdrawn.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02735876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735876.